Vanda Pharmaceuticals Inc (VNDA)
5.48
-0.10
(-1.79%)
USD |
NASDAQ |
May 17, 16:00
5.485
0.00 (0.00%)
After-Hours: 20:00
Vanda Pharmaceuticals Research and Development Expense (Annual): 76.82M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 76.82M |
| December 31, 2022 | 85.77M |
| December 31, 2021 | 75.36M |
| December 31, 2020 | 55.58M |
| December 31, 2019 | 48.65M |
| December 31, 2018 | 43.59M |
| December 31, 2017 | 38.55M |
| December 31, 2016 | 29.16M |
| December 31, 2015 | 29.14M |
| December 31, 2014 | 19.23M |
| Date | Value |
|---|---|
| December 31, 2013 | 28.50M |
| December 31, 2012 | 45.76M |
| December 31, 2011 | 29.00M |
| December 31, 2010 | 12.34M |
| December 31, 2009 | 13.87M |
| December 31, 2008 | 23.94M |
| December 31, 2007 | 47.23M |
| December 31, 2006 | 52.07M |
| December 31, 2005 | 16.89M |
| December 31, 2004 | 7.443M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
48.65M
Minimum
2019
85.77M
Maximum
2022
68.44M
Average
75.36M
Median
2021
Research and Development Expense (Annual) Benchmarks
| ADMA Biologics Inc | 3.30M |
| INVO Bioscience Inc | 0.1659M |
| Nektar Therapeutics | 114.16M |
| Ligand Pharmaceuticals Inc | 24.54M |
| Invivyd Inc | 158.66M |